SWOG clinical trial number
SWOG-9219
A Phase II Evaluation of Interleukin-4 (IL-4) in Patients with Non-Hodgkin's Lymphoma
Closed
Phase
Accrual
49%
Published
Research committees
Lymphoma
Treatment
Interleukin-4
Eligibility Criteria Expand/Collapse
biopsy proven low, intermediate or high grade NHL; measurable disease; prior therapy is required as in protocol; no AIDS or HIV; no impaired cardiac status; no CNS involvement
Publication Information Expand/Collapse
2000
Phase II evaluation of interleukin-4 in patients with non-hodgkin's lymphoma: a Southwest Oncology Group trial
Other Clinical Trials
SWOG Clinical Trial Number
S2207
Randomized Phase II Study of the Addition of Targeted Therapeutic Agents to Tafasitamab-Based Therapy in Non-Transplant-Eligible Patients with Relapse/Refractory Large B-Cell Lymphoma
Research Committee(s)
Lymphoma
Activated
06/30/2023
Accrual
7%
Open
Phase
SWOG Clinical Trial Number
CTSU/AHOD2131
A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy with Immuno-oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma
Research Committee(s)
Lymphoma
Immunomolecular Therapeutics
Activated
04/28/2023
Open
Phase
SWOG Clinical Trial Number
S2114
A Randomized Phase II trial of consolidation therapy following CD19 CAR T-cell treatment for Relapsed/Refractory Diffuse Large B-cell Lymphoma or Grade IIIB Follicular Lymphoma
Research Committee(s)
Lymphoma
Activated
02/23/2023
Accrual
15%
Open
Phase